Table 1. Baseline characteristics of the CORONA population used for the proteomic analysis.
| Characteristics | Controls | AAA | Exact p-value |
| (n = 17) | (n = 17) | ||
| Age (years), median value [25th to 75th percentile range] | 63 [56–71 | 61 |57–68] | 0.75 |
| Gender, n (% male) | 17 (100) | 17 (100) | ND |
| BMI (kg/m2), median value[25th to 75th percentile range] | 26.2 [25–27.8] | 27.7 [24.1–29.9] | 0.28 |
| Cardiovascular risk factors, n (%) | |||
| Type 2 diabetes | 5 (29.4) | 6 (35.3) | 1 |
| Arterial hypertension | 9 (52.9) | 10 (58.8) | 1 |
| Dyslipidemia | 10 (58.8) | 12 (70.6) | 0.72 |
| Smoking (past or current) | 13 (76.5 | 16 (94.1) | 0.33 |
| Positive family history for CVD | 5 (29.4) | 8 (47.1) | 0.48 |
| Personal history of CAD, n (%) | |||
| Unstable angina pectoris | 4 (23.5) | 1 (5.9) | 0.33 |
| Stable angina pectoris | 5 (29.4) | 5 (29.4) | ND |
| Peripheral arterial disease | 3 (17.6) | 6 (35.3) | 0.43 |
| Stroke | 1 (5.9) | 2 (11.8) | 1 |
| Previous myocardial infarction | 7 (41.2) | 4 (23.5) | 0.47 |
| Carotid artery stenosis | 5 (29.4) | 4 (23.5) | 0.69 |
| 1- or 2-coronary vessel disease | 2 (11.8) | 5 (29.4) | 0.40 |
| 3- or 4-coronary vessel disease | 15 (88.2) | 12 (70.6) | 0.40 |
| Major medications at time of inclusion, n (%) | |||
| Aspirin | 15 (88.2) | 13 (76.47) | 0.66 |
| Beta-blockers | 13 (76.5) | 12 (70.6) | 1 |
| ACE inhibitors | 4 (23.5) | 8 (47.1) | 0.28 |
| Calcium antagonists | 6 (35.3) | 3 (17.6) | 0.44 |
| Statins | 16 (94.1) | 12 (70.6) | 0.17 |
| Presence of other arterial aneurisms, n (%) | |||
| Iliac aneurismal extension | 0(0) | 4 (23.5) | 0.10 |
| Femoral arterial aneurism | 0(0) | 1 (5.9) | 1 |
| Popliteal arterial aneurism | 0(0) | 4 (23.5) | 0.10 |
AAA: abdominal aortic aneurysm, ACE: angiotensin converting enzyme, BMI: body mass index, CAD: coronary artery disease, CVD: cardiovascular diseases, ND: no difference between values of both groups of patients.